Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-03-06FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab (Stelara) to expand its indications, as requested by Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE) [Phase 4]
Phase 4 trial evaluating efficacy and safety of tildrakizumab 100 mg in adults with moderate to severe chronic plaque psoriasis and the impa…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating a proposed biosimilar ustekinumab (FYB202) versus Stelara in moderate-to-severe plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast [Phase 2]
Phase 2 trial update exploring monocyte biomarkers in moderate to severe plaque psoriasis patients treated with apremilast; results complete…
-
CLINICAL_TRIALS trial_result · 2022-12-20Clinical Trial Update: An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis [Phase 3]
Phase 3 trial comparing BMS-986165 (brolucizumab? note: BMS-986165 corresponds to deucravacitinib?; but based on naming, BMS-986165 is a pla…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-12-19FDA Approved: ILUMYA — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for ILUMYA (tildrakizumab) from Sun Pharmaceutical Industries, Inc., supporting a regulatory upd…
-
CLINICAL_TRIALS trial_result · 2022-12-19Clinical Trial Update: A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis [Phase 2]
Phase 2 trial of EDP1815 for mild to moderate plaque psoriasis has completed with results posted.
-
FDA approval · 2022-12-13FDA Approved: IDACIO — Original Application (Fresenius Kabi USA, LLC)
FDA approved IDACIO (adalimumab-afcf) from Fresenius Kabi USA, LLC as a biosimilar to adalimumab (Humira) under an original Biologics Licens…
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) [Phase 2]
A Phase II dose-ranging study (INDUS-3) of AUR101 in plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis [Phase 4]
Phase 4 trial update on outcomes with secukinumab treatment and withdrawal in plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis [Phase 4]
Phase 4 trial update on Ixekizumab for plaque psoriasis, including outcomes and withdrawal.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating PDE4 inhibition with roflumilast for chronic plaque psoriasis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial comparing risankizumab to methotrexate in moderate to severe plaque psoriasis completed.
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating PDE4 inhibitor roflumilast for chronic plaque psoriasis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2022-10-13Clinical Trial Update: Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) [Phase 3]
Phase 3 trial results update for tapinarof in adults with plaque psoriasis; trial completed and results posted.
-
CLINICAL_TRIALS trial_result · 2022-10-13Clinical Trial Update: Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) [Phase 3]
Phase 3 trial results for tapinarof in adults with plaque psoriasis have been completed and the results posted.
-
CLINICAL_TRIALS trial_result · 2022-10-10Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating the efficacy and safety of bimekizumab versus an active comparator in adults with moderate to severe chronic plaque…
-
CLINICAL_TRIALS trial_result · 2022-09-30Clinical Trial Update: Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis [Phase 2]
Phase 2 trial assessing safety and efficacy of ARQ-154 Foam in adolescent and adult subjects with plaque psoriasis has completed with result…
-
FDA approval · 2022-09-13FDA Approved: TAZAROTENE — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approved Cosette Pharmaceuticals' generic tazarotene through an Original Application (ANDA 215433). The product is intended for the trea…
-
FDA approval · 2022-09-09FDA Approved: SOTYKTU — Original Application (E.R. Squibb & Sons, L.L.C.)
FDA approved SOTYKTU (deucravacitinib) from its original application (NDA214958) by E.R. Squibb & Sons, L.L.C. for the treatment of plaque p…
-
CLINICAL_TRIALS trial_result · 2022-09-02Clinical Trial Update: Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis [Phase 2]
Phase 2 clinical trial evaluating safety and efficacy of DUR-928 topical solution in plaque psoriasis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-08-26Clinical Trial Update: Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis [Phase 2]
Phase 2 trial evaluating PF-07038124 ointment for atopic dermatitis and plaque psoriasis; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-08-18Clinical Trial Update: Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis [Phase 2]
Phase 2 long-term safety update for ARQ-151 cream in adults with chronic plaque psoriasis.
-
CLINICAL_TRIALS trial_result · 2022-08-10Clinical Trial Update: The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis [Phase 2]
Phase 2 trial assessing ARQ-151 cream in adults with chronic plaque psoriasis completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2022-08-08Clinical Trial Update: Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) [Phase 3]
Long-term extension data from a Phase 3 study of Tapinarof in adults with plaque psoriasis have completed. The extension results were posted…